Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Revlimid is a prescription drug used to treat certain types of blood cancers, including multiple myeloma. There are no known foods that interact with Revlimid, but there may be certain foods to ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

SARCLISA, a newly approved CD38 antibody for multiple myeloma, is gaining traction quickly. However, DARZALEX maintains a significant head start. Both drugs are competing in quadruplet regimens ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...